Abstract
2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185her2/neu, which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185her2/neu and ErbB3. In our studies of epidermal growth factor receptor (EGFR)–p185her2/neu heterodimerization, we noted that 2C4 formed associations with the EGFR–p185her2/neu receptor complex. Our data argue against 2C4 as a universal heterodimerization blocker for p185her2/neu, but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185her2/neu will emerge as the most potent targeted therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI et al. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127–137.
Berezov A, Chen J, Liu Q, Zhang HT, Greene MI, Murali R . (2002). Disabling receptor ensembles with rationally designed interface peptidomimetics. J Biol Chem 277: 28330–28339.
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL et al. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289.
Cho HS, Leahy DJ . (2002). Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297: 1330–1333.
Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney Jr DW et al. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756–760.
Cohen JA, Weiner DB, More KF, Kokai Y, Williams WV, Maguire Jr HC et al. (1989). Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4: 81–88.
Drebin JA, Link VC, Greene MI . (1988). Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2: 273–277.
Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI . (1985). Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41: 697–706.
Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI . (1984). Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 312: 545–548.
Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA . (2003). EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507–517.
Franklin MC, Carey KD, Vajdos FF, Leahy DJ, De Vos AM, Sliwkowski MX . (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.[see comment]. Cancer Cell 5: 317–328.
Guex N, Peitsch MC . (1997). SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714–2723.
Jackson JG, St Clair P, Sliwkowski MX, Brattain MG . (2004). Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64: 2601–2609.
Katsumata M, Okudaira T, Samanta A, Clark DP, Drebin JA, Jolicoeur P et al. (1995). Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1: 644–648.
Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L et al. (1990). p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184–5187.
Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG et al. (1989). Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58: 287–292.
Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665–7670.
Lodato RF, Maguire Jr HC, Greene MI, Weiner DB, LiVolsi VA . (1990). Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 3: 449–454.
Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D . (2002). Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 62: 5485–5488.
Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH et al. (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775–787.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684.
Sanner MF . (1999). Python: a programming language for software integration and development. J Mol Graph Model 17: 57–61.
Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437–441.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.
Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S et al. (2005). 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104: 2701–2708.
van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R . (1987). Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 7: 2019–2023.
Wada T, Myers JN, Kokai Y, Brown VI, Hamuro J, LeVea CM et al. (1990a). Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Oncogene 5: 489–495.
Wada T, Qian XL, Greene MI . (1990b). Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61: 1339–1347.
Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI . (1989). A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339: 230–231.
Williams TM, Weiner DB, Greene MI, Maguire Jr HC . (1991). Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 59: 46–52.
Acknowledgements
This work was partially funded by a grant from NCI (5P01 CA 89480).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Cai, Z., Zhang, G., Zhou, Z. et al. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185her2/neu and the EGFR–p185her2/neu complexes. Oncogene 27, 3870–3874 (2008). https://doi.org/10.1038/onc.2008.13
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.13
Keywords
This article is cited by
-
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
BMC Cancer (2019)
-
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
Breast Cancer Research (2018)
-
A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity
Scientific Reports (2017)
-
WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling
Oncogene (2016)
-
Monitoring serum HER2 levels in breast cancer patients
SpringerPlus (2015)